Only four of 17 analysts rate Macy’s stock as a Buy or a Strong Buy. Another 10 have Hold ratings. At a share price of around $19.90, the upside potential based on a median price target of $25.25 is 26.9%. Based on a high price target of $36.00, the potential upside on the shares is almost 81%.
Analysts are forecasting fiscal second-quarter revenue of $5.5 billion, up 2.8% sequentially and down about 2.7% year over year. Adjusted EPS are tabbed at $0.88, down 18.5% sequentially and by 31.8% year over year. For the 2023 fiscal year ending in January, analysts are looking for EPS of $4.58, down 13.7%, on sales of $24.37 billion, down about 0.4%.
Macy’s stock trades at 4.3 times expected 2023 EPS, 4.5 times estimated 2024 earnings of $4.37 and 4.9 times estimated 2025 earnings of $4.03 per share. The stock’s 52-week range is $15.85 to $37.95. The company pays an annual dividend of $0.63 (yield of 3.08%). Total shareholder return for the past year was negative 5.8%.
Medtronic
Medical device maker Medtronic PLC (NYSE: MDT) has posted a share price decline of nearly 25% over the past 12 months. Shares have traded below their 52-week high for 11 straight months, and a couple of bounces have moderated a decline that looked dangerous in mid-December.
On Thursday, the company announced an 8% increase in its quarterly dividend, the 45th consecutive year that the company has increased its dividend payment. Medtronic is one of 65 companies among the Dividend Aristocrats, and it is now just five years away from being crowned a Dividend King.
Analysts remain bullish on the stock, with 15 of 26 brokerages having a Buy or Strong Buy rating and another 10 rating the shares at Hold. At a share price of around $94.90, the upside potential based on a median price target of $109.00 is 14.9%. At the high price target of $129.00, the upside potential is nearly 36%.
Analysts expect the company to report first-quarter revenue of $7.21 billion, down 10.8% sequentially and 9.8% lower year over year. Adjusted EPS are forecast at $1.12, down 26.4% sequentially and by 20.6% year over year. Current estimates for the 2023 fiscal year ending next April call for EPS of $5.57, up 0.4%, on sales of $32.03 billion, up about 1.1%.
Medtronic’s stock trades at 17.0 times expected 2023 EPS, 15.7 times estimated 2024 earnings of $6.02 and 14.5 times estimated 2025 earnings of $6.53 per share. The stock’s 52-week range is $86.70 to $135.89. After the recent increase, the company pays an annual dividend of $2.72 (yield of 2.87%). Total shareholder return for the past year was negative 24.6%.
Originally posted at 24/7 Wall St.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
